Cardiovascular Diseases Clinical Trial
Official title:
An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study
Coronary heart disease (CHD) is the leading cause of death in the United States, but fewer than half of all individuals at risk for CHD take advantage of proven strategies to lower their chances of developing this disease. This study will assess the effectiveness of Heart to Heart, a Web-based program, at educating people on ways to incorporate CHD risk-reduction strategies into their lives.
CHD affects 13 million people in the United States. It is the leading cause of death in this
country, and each year more than half a million Americans die from this disease. People who
take steps to lower their cholesterol and blood pressure levels, lose weight, and stop
smoking may be less likely to develop CHD. However, fewer than half of all individuals at
risk for developing CHD follow these suggestions. Involving patients in the decision-making
process regarding their medical care may improve their adherence to effective CHD prevention
strategies. The goal of the Heart to Heart program is to provide information about CHD risk
factors and encourage people to incorporate the appropriate risk-reduction measures into
their lives. The purposes of this pilot study are to evaluate the ability of study
researchers to recruit individuals with a moderate to high risk of CHD to participate in the
study; to conduct a four-part CHD intervention (Heart to Heart) in a busy medical practice
setting; and to measure participants' decision-making plans, self-reported adherence to
medications, and changes in overall CHD risk factors. The results from this study will be
used to guide future clinical trials.
This study will enroll patients being treated at the General Internal Medicine Clinic at the
University of North Carolina at Chapel Hill who have a moderate to high risk of developing
CHD. At an initial study visit, participants will complete questionnaires that assess CHD
risk-reduction strategies, smoking status, and aspirin use. Blood pressure and cholesterol
levels will also be measured. Participants will then be randomly assigned to either
participate in the Heart to Heart intervention or receive usual care. Participants in the
intervention group will access Heart to Heart, a Web site designed to educate them about
their overall CHD risk, specific risk factors, and strategies and preferences for risk
reduction. A Web-based coaching tool will encourage participants to talk with their doctor
about risk-reduction choices. Participants will also receive brief adherence messages via
the Web site 2, 4, and 6 weeks following their initial study visit. The messages will be
designed to help participants adhere to their decisions. All participants will attend a
study visit at Month 3 for repeat baseline testing. Following this visit, participants will
receive a letter that includes their test results and their recalculated CHD risk.
Participants may be contacted to take part in a focus group following the completion of the
study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|